Guggenheim reiterates LB Pharmaceuticals stock rating on study data

Guggenheim reiterated a Buy rating and $80.00 price target on LB Pharmaceuticals Inc (NASDAQ:LBRX) following new preclinical study results. The study presented at the ECNP congress provides direct functional evidence that orally administered LB-102 engages presynaptic dopamine D2/D3 autoreceptors in the rat nucleus accumbens. This confirms the mechanistic premise of the bimodal dose thesis underpinning the multi-indication model, supporting ongoing trials for bipolar depression and major depressive disorder.

LB Pharmaceuticals has seen a surge in activity surrounding its lead drug candidate, LB-102, with various analysts expressing confidence in the company's pipeline and potential future indications.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.